Prediction of In Vivo Rat Biliary Drug Clearance from an In Vitro Hepatocyte Efflux Model

Patrik Lundquist, Johan Lööf, Urban Fagerholm, Ingemo Sjögren, Jenny Johansson, Sveinn Briem, Janet Hoogstraate, Lovisa Afzelius, and Tommy B. Andersson

ABSTRACT

Well-established techniques are available to predict in vivo hepatic uptake and metabolism from in vitro data, but predictive models for biliary clearance remain elusive. Several studies have verified the expression and activity of ATP-binding cassette (ABC) efflux transporters central to biliary clearance in freshly isolated rat hepatocytes, raising the possibility of predicting biliary clearance from in vitro efflux measurements. In the present study, short-term plated rat hepatocytes were evaluated as a model to predict biliary clearance from in vitro efflux measurements before major changes in transporter expression known to take place in long-term hepatocyte cultures. The short-term cultures were carefully characterized for their uptake and metabolic properties using a set of model compounds. In vitro efflux was studied using digoxin, fexofenadine, napsagatran, and rosuvastatin, representing compounds with over 100-fold differences in efflux rates in vitro and 60-fold difference in measured in vivo biliary clearance. The predicted biliary clearances from short-term plated rat hepatocytes were within 2-fold of measured in vivo values. As in vitro efflux includes both basolateral and canalicular effluxes, pronounced basolateral efflux may introduce errors in predictions for some compounds. In addition, in vitro rat hepatocyte efflux uptake rates corrected for simultaneous efflux predicted rat in vivo hepatic clearance of the bile cleared compounds with less than 2-fold error. Short-term plated hepatocytes could thus be used to quantify hepatocyte uptake, metabolism, and efflux of compounds and considerably improve the prediction of hepatic clearance, especially for compounds with a large biliary clearance component.

Introduction

Transport processes such as hepatic uptake or biliary efflux are central to the clearance (CL) of many drug compounds (Giacomini et al., 2010). Hepatic drug metabolism is performed by enzymes commonly divided into phase I enzymes (mainly cytochrome P450, P450) and phase II enzymes (conjugating enzymes such as UDP-glucuronosyltransferase, UGT). A special challenge is to predict the in vivo pharmacokinetics (PK) of compounds that are subject to a combination of uptake, metabolism, and efflux (Li et al., 2010).

Today, several techniques for investigation of hepatocyte uptake and metabolism of drug molecules are available, such as metabolic stability or uptake measurements using suspended hepatocytes (Soars et al., 2007). However, because isolated hepatocytes lose their tissue geometry, active efflux and biliary secretion of compounds are properties difficult to study in vitro (Li et al., 2010; De Bruyn et al., 2013). Robust in vitro models that also reflect biliary efflux in addition to hepatic uptake and metabolism would be valuable tools to evaluate drug disposition as well as the in vitro to in vivo extrapolation (IVIVE) of hepatic clearance. Compounds actively cleared by biliary or renal secretion belong in general to classes III and IV of the Biopharmaceutics Drug Disposition Classification System (BDDCS) proposed by Wu and Benet (2005). These classes are characterized by low metabolism, low permeability, and large transporter effects. Classes I and II are characterized by high metabolism and permeability and small transporter effects.

Sandwich-cultured hepatocytes (SCH) are a convenient in vitro model to use for biliary clearance studies because the hepatocytes after 4 to 5 days of culture develop a rudimentary canalicular network and polarized membrane expression of many transporters. The excretion of compounds into the canalicular compartment is used to calculate the biliary excretion (Liu et al., 1999; De Bruyn et al., 2013). This strategy has been successful in predicting the bile efflux of several drugs, but as noted by Li et al. (2010) and others, it often underpredicts biliary clearance by 10-fold to 100-fold (Nakakariya et al., 2012; De Bruyn et al., 2013). Partly this may be due to the down-regulation of both
drug uptake and efflux transporters that has been demonstrated to take place within the first days after the plating of hepatocytes from both rats and humans (Liu et al., 1998; Li et al., 2009a; Kotani et al., 2011; Tchaparian et al., 2011; Kimoto et al., 2012; De Bruyn et al., 2013). Sinousoidal efflux transporters, such as rat multidrug resistance-associated protein 3 (MRP3) and rat organic solute transporter α–organic solute transporter β (rOSTα-OSTβ) show low expression levels in normal livers but are up-regulated in cholestasis (Rippin et al., 2001; Luttringer et al., 2002; Boyer et al., 2006). The expression levels of rMRP4 and rMRP3 in rat liver, primary hepatocytes, and short-term cultures are low, but they are extensively up-regulated in longer term cultures (Rippin et al., 2001; Luttringer et al., 2002; Tchaparian et al., 2011). In addition the activity of many P450 enzymes is considerably reduced in SCH (De Bruyn et al., 2013). To compensate for expression changes in SCH, proteomics-based correction factors have been used with some success, but these are difficult to implement when the transporters involved in the disposition of a compound are not known (Li et al., 2010).

The fate of canicular ATP-binding cassette (ABC) efflux transporters central to biliary excretion such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance protein-2 (MRP2) in isolated hepatocytes has been debated. Some reports suggest that isolated rat hepatocytes lose part of their ABC transporters (Bow et al., 2008). Others studies have demonstrated both expression and activity of P-gp, rBCRP, and MRP2 in freshly isolated rat hepatocytes (Lam et al., 2006; Li et al., 2008, 2009a; Lundquist et al., 2014a). The retained activity of canicular efflux transporters in primary rat hepatocytes demonstrated by these investigators raises the possibility of predicting biliary clearance from in vitro efflux measurements.

Short-term cultures may be a reliable in vitro model for studies on drug disposition as changes in hepatocyte transporter and drug metabolizing enzyme expression and activity are minor after 4 to 6 hours of culture (Jigorel et al., 2005; Beigel et al., 2008; Tchaparian et al., 2011). In our present study, short-term cultures were demonstrated to be a robust model to predict the biliary clearance of a set of compounds with a large range of biliary clearances in vivo. Predictions were within 2-fold of measured biliary clearances, which is a considerable improvement compared with published methods. In addition, uptake and metabolic clearances were evaluated using short-term plated hepatocytes, and the results indicate that the model provides the possibility of assessing uptake, metabolic, and efflux clearances.

Material and Methods

Nomenclature. This article, as recommended by Hagenbuch and Stieger (2013), for transporter nomenclature follows the gene and protein nomenclature guidelines of the HUGO Gene Nomenclature Committee (Gray et al., 2013) and the International Committee for Standardized Genetic Nomenclature in Mice (http://www.informatics.jax.org/mgihome/nomen/2009_gene.shtml) (2009). Protein names for both human and rodent proteins are written in capital letters (e.g., BCRP). In the interest of clarity human protein names are prefixed with h, and rat proteins are prefixed r (e.g., hBCRP, rBCRP). Protein names without prefix refer to the protein in general, not belonging to any particular species (e.g., a BCRP inhibitor).

Chemicals. Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.

Animals. Male Sprague-Dawley rats were acquired from Harlan Laboratories B.V. (Venray, the Netherlands). Rats were housed up to three per cage with free access to food and water. All animals were acclimatized for 2 weeks before the studies. All animal experiments were approved by the local animal ethics committee (Stockholms Södra djurförskötselsnämnd) and were conducted in compliance with national guidelines for the care and use of laboratory animals.

Preparation of Rat Hepatocytes. Rat hepatocytes were isolated according to a modified collagenase perfusion method previously described elsewhere (Bissell and Guzelian, 1980) from 7- to 8-week-old male Sprague-Dawley rats that were anesthetized with isoflurane (Abbott Scandinavia AB, Kista, Sweden). Shortly afterward, the liver was perfused in situ, first with 37°C calcium-free William’s E (WE) medium containing 0.5 M EGTA, followed by WE medium, 10 mM HEPES (GIBCO/Life Technologies, Paisley, United Kingdom), pH 7.4, supplemented with 0.16 mg/ml collagenase type XI. The suspension of released hepatocytes was filtered through gauze, repeatedly centrifuged at 50g for 2 minutes, followed by aspiration of supernatant and resuspension of the pellet in WE, 10 mM HEPES, pH 7.4. Cell number and viability were determined using the Trypan blue exclusion method. Viability typically exceeded 90%. Cell preparations with viability of <80% were discarded.

Uptake and Metabolism Measurements of Test Compound with Plated Rat Hepatocytes and Suspended Cells. We seeded 0.75 million cells from a suspension of 10³ cells/ml in culture medium [WE supplemented with 10 mM HEPES, pH 7.4, 10% fetal calf serum, 2 mM glutamine, and 0.01% insulin-transferrin-selenium A solution (GIBCO)] into each well of collagen I-coated 12-well plates (Biocoat; BD Biosciences, Franklin Lakes, NJ). The cells were incubated at room temperature for 10 minutes and were then left to attach to the plates for 90 minutes at 37°C in 5% CO₂. The plates were washed three times in 37°C Krebs-Henseleit buffer with 10 mM HEPES (GIBCO) pH 7.4 (KHL). Cells were preincubated in KHL at 37°C for 10 minutes before each experiment.

To start the uptake, KHL was removed, and 300 µl of 1 µM of test compound diluted in KHL and containing 0.1% dimethylsulfoxide (DMSO) was added to each well. Each time point was measured in triplicate. To stop the uptake reaction, 200 µl buffer from each well was transferred to a 96-well plate containing 300 µl of stop solution of acetonitrile (ACN) with 200 mM Warfarin (internal standard). The remaining buffer was removed, and the wells were washed twice in ice-cold KHL. The cell layer in washed wells was lysed with 300 µl of lysis solution, 2 parts of stop solution, and 1 part KHL with 200 mM warfarin. The lysates were incubated on ice for at least 10 minutes, then mixed and centrifuged at 1200g for 10 minutes. Before analysis, each fraction was diluted in KHL to contain 25% ACN. All samples were analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Binding was measured in empty plates and subtracted from the uptake measurements.

The activity of drug phase I and II metabolizing enzymes in rat hepatocytes in suspension and attached to plates was compared using a cocktail containing substrates for several CYP and phase II enzymes: 7-hydroxycoumarin (UGT), bufuralol (CYP2D2), diazepam (CYP2C11), diclofenac (CYP2C6), midazolam (CYP3A), and phenacetin (CYP1A2), each at 3 µM final concentration (isoform specificities from Kobayashi et al., 2002). Hepatocytes in suspension (10³/ml) in KHL were incubated with the cocktail for 0 to 90 minutes. Samples were precipitated with 2 volumes of stop solution. Cells attached to plates were processed as was described for the uptake experiments.

For comparative purposes in IVIVE, the metabolic stability in rat liver microsomes was determined as described by Sohlhus-Sternbeck et al. (2010).

To test uptake activity in suspended and plated rat hepatocytes, five well-characterized uptake transporter substrates (atorvastatin, bosentan, estrone-3-sulfate, fexofenadine, and montelukast) and two passively transported substrates (atenolol and metoprolol; AstraZeneca) were tested. Experiments in plated cells were performed as described previously. The uptake measurements in suspended cells were performed using the media loss technique described by Soars et al. (2007).

To further investigate active transport in plated cells, atorvastatin uptake measurements were performed in the absence and presence of 2 µM of the organic anion transporting polypeptide (OATP) inhibitor cyclosporine A. The activity of Na⁺-taurocholate cotransporting polypeptide (NTCP) in plated cells was studied by comparing the uptake of taurocholate in sodium-containing buffer and sodium-free buffer, substituted with equimolar choline. The influence of temperature on passive uptake in plated rat hepatocytes was investigated using the passively uptaken substrate atenolol at 37°C and 4°C.

In Vitro Efflux Measurements. Four compounds with complete human in vivo PK were identified: digoxin, napsagatran, fexofenadine, and rosuvastatin. Napsagatran was a kind gift from Hoffman-La Roche, Basel, Switzerland. Inclusion criteria were plasma clearance (Cl_plasma) and biliary clearance (Cl_biliary) measured after intravenous administration of a compound and the published values on human plasma protein binding and blood-to-plasma concentration ratio (C₀₈₀/C₀₈₀).
Hepatocytes in 12-well plates were preloaded until a maximal intracellular concentration was reached, as described for the uptake experiments. Measuring the compound efflux at maximal intracellular concentration gives the efflux at steady state. Preload times and compound concentrations were decided from measured uptake data in pilot experiments (digoxin, 10 μM for 15 minutes; fexofenadine, 1 μM for 30 minutes; napsagatran, 10 μM for 30 minutes; and rosuvastatin, 1 μM for 15 minutes). After preloading, the wells were washed three times in 37°C KHL to ensure that the wells were free from remaining compound. Efflux experiments were started by adding 300 μl KHL (37°C) to each well. Cells were also lysed immediately after washing to determine the initial intracellular concentrations at the start of the experiment. The contribution of ABC-efflux transporter activity to the measured efflux was assayed using 0.5 μM of the inhibitors elacridar (GF120918, [N-(12-[(2,3,4,5-tetrahydro-6,7-dimethoxy-2-isoxazolyl)(ethyl)-(phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide hydrochloride]), a P-gp and BCRP inhibitor, and fumitremorgin C (FTC), a BCRP inhibitor.

Triplicate wells from uptake and efflux experiments were lysed with 200 μl 1% SDS, and the protein concentration was determined with the BCA protein assay kit (Pierce Biotechnology/ThermoFisher Scientific, Rockford, IL). The hepatocyte number per well was calculated using published data (Sohlenius-Assay kit (Pierce Biotechnology/ThermoFischer Scientific, Rockford, IL). The software MassLynx was used to control the liquid chromatography system and mass spectrometer (Waters Corporation, Milford, MA). A high purity C18 5 μm 2.1 mm (Thermo Electron Corporation, Waltham, MA) analytical column was used. A standard curve was included for each compound analyzed, spanning a concentration range from twice the initial experimental concentration to below the limit of quantification. The limit of quantification, the signal to noise ratio for detection, was set to 5 times.

Determination of Plasma Protein Binding. Plasma protein binding was determined by equilibrium dialysis. Rat plasma was mixed with the compound at a concentration of 10 μM (in 0.1% DMSO). A volume of 180 μl 0.122 M phosphate buffer, pH 7.4, and 7.5 mM NaCl was added to each well on one side of a dialysis plate, and 180 μl of the plasma/compound mix to the opposite side, separated by a dialysis membrane (Spectra/Por MWCO 6-8000; Spectrum Laboratories, Rancho Dominguez, CA). After incubation on an orbital shaker at 37°C for 18 hours, the samples were analyzed by LC-MS/MS. All compounds were stable during the 18-hour incubation.

Determination of Blood-to-Plasma Concentration Ratio (Cblood/plasma). The Cblood/plasma was determined in fresh rat whole blood for digoxin, fexofenadine, napsagatran, rosuvastatin, and midazolam (positive control). Two blood samples were spiked with 0.2 μM test compound and incubated on a wadding mixer at 37°C for 1 hour. The blood was centrifuged, and the resulting plasma was analyzed by LC-MS/MS.

Plasma Clearance of Test Compound. Blood samples were drawn from male Sprague-Dawley rats aged approximately 8 weeks just before and at 1, 5, 20, and 40 minutes, and at 1, 1.5, 3, 6, and 24 hours after intravenous bolus administration of 3 μmol/kg of test compound (in 0.3 M N-methyl-D-glucamine). Standards and samples were diluted in blank plasma and analyzed by LC-MS/MS.

Bile Clearance of Test Compound. Male Sprague-Daley rats aged approximately 8 weeks were anesthetized with isoflurane (Abbott) by use of a vaporizer and were then surgically prepared with a bile-pancreatic catheter (constructed by polyethylene catheter Physiocath and P90; Data Sciences International, St. Paul, MN). A small incision was made in the duodenum, and the catheter was inserted for the recycling of bile. A skin incision was made in the scapula region. The scapula was exposed and was then secured with a draconic button. After 3 days’ recovery, the animals were connected to a swivel system (Instech Laboratories, Plymouth Meeting, PA) that allowed freedom of movement during the experiment; they were then administered a bolus dose of 3 μmol/kg of compound via a lateral caudal vein. Fractions of bile were collected every 10 minutes for the first hour and every hour until 6 hours after dosing. Plasma was drawn at 6 hours after dosing. The animals were finally sacrificed with an overdose of the barbiturate pentobarbital, veterinary grade (Apoteket Produktion & Laboratorier AB, Kungens Kurva, Sweden). Standards and samples were diluted in a 1:10 dilution of blank bile and analyzed by LC-MS/MS.

LC-MS/MS Analysis. Analysis of parent compounds and metabolites was performed by LC-MS/MS using a Micromass Quattro Micro triple quadrupole (Micromass, Manchester, United Kingdom). The software MassLynx was used to control the liquid chromatography system and mass spectrometer (Waters Corporation, Milford, MA). A high purity C18 5 μm 30 × 2.1 mm (Thermo Electron Corporation, Waltham, MA) analytical column was used. A standard curve was included for each compound analyzed, spanning a concentration range from twice the initial experimental concentration to below the limit of quantification. The limit of quantification, the signal to noise ratio for detection, was set to 5 times.

Pharmacokinetics and IVIVE

Determination of In Vitro Intrinsic Clearance. The elimination rate constant in metabolic stability and uptake experiments was calculated from the first-order elimination equation:

\[ \frac{d[S]}{dt} = -k \cdot [S] \]  

(1)

where [S] is concentration of substrate at a given time point \( t \), \( [S]_0 \) is the initial concentration of substrate, and \( k \) is the elimination rate constant, which was determined by nonlinear regression within a time point interval representing the initial elimination rate (Soars et al., 2007). For in vitro efflux, \( k \) is given by the rate of compound effluxed into the medium.

In vitro intrinsic clearances (CLint,met, CLint,uptake, CLint,efflux) for the compounds could then be calculated from:

\[ CL_{int} = k \cdot V \]  

(2)

where \( V \) represents the volume of incubation. CLint,efflux is calculated using the volume and concentration of the preloading medium. This is the rate of efflux back into the medium when uptake experiments have reached steady state.

Intrinsic hepatic clearance according to the extended clearance concept incorporating both transport and metabolism is given by:

\[ CL_{int,all} = \frac{(CL_{int,efflux} + CL_{int,met})}{(CL_{int,efflux} + CL_{int,met} + CL_{int,back})} \]  

(3)

(Maeda and Sugiyama, 2010). CLint,uptake is the uptake CLint,CLint,efflux is the efflux of compound from hepatocytes to bile, CLint,met is the metabolic CLint, and CLint,back is the basolateral efflux from hepatocytes back to the circulation. Our in vitro efflux experiments cannot distinguish CLint,efflux and CLint,back, so CLint,back was arbitrarily set to 0 for these experiments to allow calculations (see Discussion for further details).

When CLint,back = 0, we have a compound with no sinusoidal active efflux and little passive permeability (i.e., a BDCCS class III or IV compound without sinusoidal active efflux) (Benet et al., 2011). All biliary probe compounds in this study are BDCCS class III compounds with unknown sinusoidal active efflux. CLint,all is this case determined by the hepatocyte uptake:

\[ CL_{int,all} = CL_{int,uptake} \]  

(4)

However, in our in vitro experiments efflux is active, and the measured uptake is an apparent uptake diminished by the active efflux of the compound back into the medium. To compensate for this, the total uptake CLint is calculated:

\[ CL_{int,all} = CL_{int,uptake, total} = CL_{int,uptake} + CL_{int,efflux} \]  

(5)

This equation gives the uptake rate that would be seen after complete inhibition of active efflux.

Fraction Unbound in the Incubations. The fraction unbound (fu) in the hepatocyte incubation was predicted according to Kilfoil et al. (2008):

\[ fu_{luc, hep} = \frac{1}{1 + 125 \times \frac{V_{g}}{10^8} \times 0.072 \times \log P \times D^{-0.067} \times \log P \times D^{-1.126}} \]  

(6)

where \( V_g \) is the ratio between the cell volume and the incubation volume with a value of 0.005 at the cell concentration 10⁶ cells/ml. Log P is used for bases, and log D for other ion classes. Predicted log P and log D values were generated using a commercial package from Advanced Chemistry Development (Toronto, Canada).
Intravenous fuplasma Xt

where the hepatic fraction, Xt, where

denotes the amount secreted in bile between the two time points and AUCblood,t1–t2 is the blood area under the concentration-time curve (AUC) for the same time interval (Fukuda et al., 2008). In this study, the time interval spans the first hour after intravenous administration of compound.

In vivo hepatic clearance, CLhepatic, is calculated according to:

$$CL_{hepatic} = CL_{blood} \times f_{hepatic}$$

where the hepatic fraction, $f_{hepatic}$, for the biliary cleared test compounds is given in the literature (Lavé et al., 1999; Kamath et al., 2005; Yang et al., 2009). CLhepatic comprises both metabolic and biliary efflux clearances.

**Calculation of Fraction Unbound in the Blood.** The fraction unbound in the blood ($f_{ublood}$) was calculated using the following equation:

$$f_{ublood} = \frac{f_{uplasma}}{(C_{blood}/C_{plasma})}$$

**Prediction of In Vivo CLint.** The predicted CLint,in vivo for the liver was calculated as follows:

$$Predicted \ CL_{int\ in\ vivo} = CL_{int\ in\ vitro} \times \text{physiological scaling factors} \times f_{int\ hep}$$

The physiologic scaling factors for rat hepatocytes were: (120 x 10^6 cells/g liver) x (10 g liver/250 g body weight) (Bayliss et al., 1990; Sohlenius-Sternbeck 2006). CLint,in vitro can be either CLint,uptake, CLint,efflux, CLint,met (all from eq. 2), or CLint,uptake,met (eq. 3 to eq. 5), which are then used to predict CLhepatic or CLbile using eq. 13.

**Prediction of In Vivo CL from In Vitro Data.** Predictions were based on the well-stirred model:

### TABLE 1

A comparison of metabolic CLint for several phase I and II metabolic substrates in plated rat hepatocytes and suspended cells.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>BDDCS Class</th>
<th>Main Metabolic Enzyme</th>
<th>CLint (μl/min x 10^6 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plated Cells</td>
</tr>
<tr>
<td>Bufuralol</td>
<td>I</td>
<td>CYP2D2</td>
<td>64 ± 12</td>
</tr>
<tr>
<td>Diazepam</td>
<td>I</td>
<td>CYP2C11</td>
<td>24 ± 6</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>I</td>
<td>CYP2C6</td>
<td>23 ± 5</td>
</tr>
<tr>
<td>7-Hydroxycoumarin</td>
<td>I</td>
<td>UGT</td>
<td>38 ± 24</td>
</tr>
<tr>
<td>Midazolam</td>
<td>I</td>
<td>CYP3A</td>
<td>40 ± 9</td>
</tr>
<tr>
<td>Phenacetin</td>
<td>II</td>
<td>CYP1A2</td>
<td>29 ± 4*</td>
</tr>
</tbody>
</table>

Mean ± S.D. is shown, n = 3 for plated cells, >100 for suspended cells (long-term laboratory average). Statistical significance was tested with the two-tailed Student’s t test. *P < 0.05, significantly lower than in suspended hepatocytes.

* BDDCS classes as described by Benet et al. (2011).

**TABLE 2**

Comparison of uptake rates (CLint,uptake) for plated rat hepatocytes and suspended cells.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>BDDCS Class</th>
<th>Uptake Transporter</th>
<th>CLint (μl/min x 10^6 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plated Cells</td>
</tr>
<tr>
<td>Atenolol</td>
<td>III</td>
<td>None</td>
<td>1.2 ± 0.2***</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>I</td>
<td>None</td>
<td>10 ± 2**</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>II</td>
<td>OATPs</td>
<td>30 ± 3</td>
</tr>
<tr>
<td>Bosentan</td>
<td>II</td>
<td>OATPs</td>
<td>11.5 ± 3</td>
</tr>
<tr>
<td>Estrone-3-sulfate</td>
<td>III</td>
<td>NTCP/OATs/OATPs</td>
<td>75 ± 9**</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>III</td>
<td>OATPs</td>
<td>3 ± 0.5**</td>
</tr>
<tr>
<td>Terfenadine</td>
<td>II</td>
<td>None</td>
<td>153 ± 19**</td>
</tr>
<tr>
<td>Montelukast</td>
<td>II</td>
<td>OATPs</td>
<td>145 ± 20</td>
</tr>
</tbody>
</table>

Mean ± S.D. is shown, n = 3. Statistical significance was tested with the two-tailed Student’s t test. ** P < 0.01, *** P < 0.001.

* BDDCS class as described by Benet et al. (2011).

* Transporter data are from the University of Tokyo and University of California–San Francisco and U.S. Food and Drug Administration (UCSF-FDA) online transporter databases (Ozawa et al., 2004; Morrissey et al., 2012); http://bts.ucsf.edu/fdatransportal.

* Compounds with predominantly passive uptake cannot be assigned to estrone-3-sulfate, no true BDDCS class assignment can be given, except to note that it is a highly soluble compound with little passive permeability.
Hepatic blood flow, \( Q_{h,b} \), was set to 72 ml/min/kg for the rat (Brown, et al., 1997). CL\textsubscript{bile} was predicted from CL\textsubscript{int,efflux} and CL\textsubscript{hepatic} for comparative purposes predicted from CL\textsubscript{int,met}, CL\textsubscript{int,uptake} and CL\textsubscript{int,uptake,total} (using eq. 12 and eq. 13).

Statistical Analysis. Data were analyzed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Data are given as mean ± S.D. Statistical significance was tested using the two-tailed Student’s \( t \) test (\(*P < 0.05; ** = P < 0.01; *** = P < 0.001\)). \( P < 0.05 \) was considered statistically significant.

**Results**

**Plating of Hepatocytes.** After plating, the hepatocytes formed a loosely confluent layer exhibiting a cobblestone appearance (data not shown). Experiments started within 4 hours of liver collagenase perfusion, including 90 minutes of plating.

**Metabolism and Uptake in Plated Cells.** A range of highly permeable BDDCS class I and II compounds (Benet et al., 2011), known to be metabolized by CYP and UGT enzymes, were used to assess drug metabolic capacity in plated and suspended rat hepatocytes. The results presented in Table 1 indicate that short-term plated hepatocytes retain similar metabolic capacity as freshly isolated cells.

Uptake rates for a number of well-characterized uptake substrates from high and low permeable BDDCS classes were compared in plated and suspended hepatocytes (Table 2). The CL\textsubscript{int,uptake} of atorvastatin, bosentan, and montelukast, which are predominantly dependent on transporters to be taken up by cells, was similar in plated and suspended hepatocytes. However, the uptake rates of estrone-3-sulfate and fexofenadine, well-known transporter substrates, were higher in suspended than in plated cells. Atenolol, metoprolol, and terfenadine, substances that are well-known transporter substrates, was similar in plated and suspended hepatocytes. However, the uptake rates of estrone-3-sulfate and fexofenadine, well-known transporter substrates, were higher in suspended than in plated cells. Atenolol, metoprolol, and terfenadine, substances that are well-known transporter substrates, were higher in suspended than in plated cells.

**Properties of the Selected Test Set of Biliary Cleared Compounds.** The selected biliary cleared compounds exhibited diverse clearance pathways and drug transporter involvement (Table 3). The compounds showed low to moderate plasma protein binding, diverse lipophilicities, and limited passive permeability (BDDCS class III) (Benet et al., 2011).

In Vitro Pharmacokinetic Properties of the Biliary Cleared Compounds. The compounds showed limited metabolic CL\textsubscript{int} (Table 4). All compounds in the test set were taken up by plated rat hepatocytes (Table 4). Efflux measurements for all compounds were performed after preloading when the compound had reached a maximal intracellular concentration.

The decreasing intracellular amount and efflux of compound from the cells into the medium was measured as illustrated in Fig. 1, A and B, for rosuvastatin. CL\textsubscript{int,efflux} values for the tested compounds are given in Table 4. The measured CL\textsubscript{int,efflux} values were 0.13 ± 0.06, 3.2 ± 0.6, 10.1 ± 2.3, and 110 ± 2.8 for digoxin, fexofenadine, napsagatran, and
Rosuvastatin, respectively, thus representing drugs with a >800-fold range of efflux rates. As efflux in these experiments counteracts and diminishes uptake measurements, CL-int,uptake,total was calculated according to eq. 5.

Bile flow was similar between animals and over time during the collection period (28 ± 5 μl/min, mean ± S.D., n = 8). There was no correlation between bile flow and secretion rate or between bile flow and the amount of compound excreted in bile.

Biliary CL (CL-bile) was calculated according to eq. 9 (Fukuda et al., 2008) and is presented in Table 4. Biliary CL constituted a significant portion of the clearance of all tested compounds. In vitro efflux and in vivo CL-bile showed the same rank order of rosuvastatin > napsagatran > fexofenadine > digoxin (Table 4).

**In Vitro-In Vivo Extrapolation.** When CL-hepatic was predicted from hepatocyte or microsomal metabolic CL-int,met using the well-stirred model (eq. 12 and eq. 13; Table 4), an absolute average fold error of more than 10-fold was obtained, and the slope of the best fit line was not significant (data not shown).

The CL-bile of digoxin, fexofenadine, napsagatran, and rosuvastatin was well predicted from CL-int,efflux using the well-stirred model (eq. 12 and eq. 13; Table 4). Extrapolations showed an even distribution of overpredictions and underpredictions and an absolute average fold error of 1.7. Digoxin, fexofenadine, and napsagatran CL-bile was predicted within 2-fold of measured in vivo values, while the prediction for rosuvastatin showed an error of 2.2-fold (Table 4). The best fit line of the IVIVE data showed r² = 0.89, and its slope was significantly different from 0 (Fig. 2A).

The results from our present study indicate that scaling CL-hepatic of digoxin, fexofenadine, napsagatran, and rosuvastatin from plated rat hepatocyte CL-int,uptake (eq. 12 and eq. 13; Table 4) consistently underpredicted in vivo observations with errors ranging from 1.6- to 10-fold. The best fit line was not significantly different from 0 (Fig. 2B; Table 4).

Because active efflux in the plated hepatocytes will affect uptake measurements, CL-int,uptake,total was calculated according to eq. 5.
Prediction of Rat Biliary Clearance

Rat CL<sub>bile</sub> using rat SCH efflux in the traditional manner yielded concentrations and free intracellular concentrations in rat SCH. Predicting that biliary clearance predictions from rat SCH can be considerably improved. Three out of four compounds were slightly underpredicted. Predictions of CL<sub>bile</sub> for digoxin, fexofenadine, and napsagatran were within 2-fold of observed in vivo values, whereas the prediction for rosuvastatin showed an error of 2.1-fold. The absolute average fold error of the predictions was 1.7 (Table 4). The best fit line of the IVIVE data showed an \( r^2 = 0.84 \), and its slope was significantly different from 0 (Fig. 2C).

**Discussion**

Short-term plated hepatocytes have previously been used for kinetic characterization and modeling of hepatic drug uptake and metabolism, but little attention has been paid to the impact of active efflux in the system (Menochet et al., 2012a, b). The active efflux component may have a major influence on cellular kinetics and thus merits further investigation. As demonstrated in our study, active efflux of digoxin, fexofenadine, napsagatran, and rosuvastatin in short-term plated rat hepatocytes predicts biliary clearance within 2-fold, and inclusion of the efflux component in IVIVE of hepatic clearance from in vitro uptake data improved predictions considerably.

Rat CL<sub>bile</sub> rates of digoxin, fexofenadine, napsagatran, and rosuvastatin as predicted from in vitro efflux data from plated rat hepatocytes were not related to a general underprediction of the studied compounds as often experienced using other in vitro systems. Earlier attempts to scale rat in vivo CL<sub>bile</sub> from rat SCH efflux, incorporating \( f_m^{blood} \), for the biliary cleared compound set resulted in 1.6-fold (digoxin), 3.5-fold (fexofenadine), and 15- to 17-fold (rosuvastatin) underpredictions (Anmaert et al., 2001; Turncliff et al., 2006; Fukuda et al., 2008; Nakakariya et al., 2012). Nakakariya et al. (2012) have recently shown that the prediction of liver concentrations using intracellular SCH and liver concentrations improved the results, giving underpredictions with an average fold error of 4.5, representing the most successful in vitro method to date for the prediction of biliary clearance (Nakakariya et al., 2012).

Although a few previous studies have suggested that isolated rat hepatocytes lose part of their ABC transporters (Bow et al., 2008), others have demonstrated both expression and activity of efflux transporters in freshly isolated rat hepatocytes (Lam et al., 2006; Li et al., 2008, 2009a,b,c). In a recent study, we demonstrated retained protein levels, membrane localization, and activity for BCRP, rP-gp, and rMRP2 in freshly isolated rat hepatocytes as well as cryopreserved human hepatocytes (Lundquist et al., 2014a). In our present study, efflux from preloaded rat hepatocytes could be inhibited with well-characterized ABC efflux transporter inhibitors, indicating that rBCRP and rP-gp are active in short-term cultured hepatocytes.

Despite the compounds being cleared by a wide range of mechanisms and being substrates of many different transporters as listed in Table 3, the prediction errors were similar for all compounds tested. Investigation of bile clearance using the in vitro model proposed in our study will best predict in vivo biliary clearance for compounds exhibiting limited sinusoidal efflux, low passive permeability, and low lipophilicity/low unspecific cellular binding. These are characteristics shared by many compounds with pronounced biliary clearance (Yang et al., 2009). Short-term cultures of human cryopreserved hepatocytes should be investigated in future studies to help improve predictions of human biliary clearance. However, the pronounced down-regulation of OATP transporters that was recently demonstrated in human cryopreserved hepatocytes might present a limitation (Kimoto et al., 2012; Lundquist et al., 2014b).

Scaling CL<sub>bile</sub> from plated rat hepatocyte uptake data, the in vivo values were consistently underpredicted in our present study. Similar results were obtained by Gardiner and Paine (2011), who noted a 6-fold underprediction from rat hepatocyte uptake data. Menochet et al. (2012b) also presented underpredictions of in vivo hepatic uptake from in vitro uptake measurements using rat hepatocytes. As can be seen in Table 4 and Fig. 2B, the underprediction of CL<sub>bile</sub> from plated hepatocyte uptake data became larger for compounds with

![Fig. 1.](image-url)
higher efflux rates. In the study by Menochet et al. (2012b), rosuvastatin needed the largest correction factor and is also the compound with the highest CL bile in vitro efflux.

Due to active efflux from the hepatocytes, the true cellular uptake is probably underestimated. We recently showed that the apparent

fig. 2. In vitro–in vivo extrapolation of rat PK from Table 4. (A) Prediction of in vivo CL bile from plated hepatocyte CL int,efflux. (B) Prediction of in vivo CL hepatic from plated hepatocyte CL int,uptake. (C) Prediction of in vivo CL hepatic from plated hepatocyte CL int,uptake,total. The line of unity between extrapolation and observation as well as lines representing 2-fold errors are shown by dotted lines. The best fit line from linear regression is represented by a solid line with an $r^2$ value for 6A. The best fit line in 6C shows an $r^2 = 0.84$ and a significant slope ($P < 0.05$) for 6A. The best fit line in 6C shows an $r^2 = 0.84$ and a significant slope ($P < 0.05$). D, digoxin; F, fexofenadine; N, napsagatran; R, rosuvastatin. (Mean ± S.D., n = 3.)

fexofenadine uptake in rat hepatocytes increased more than 4-fold when inhibiting P-gp during the uptake experiment (Lundquist et al., 2014b), supporting this hypothesis. As clearly shown in our present study, compensating for active efflux in the plated hepatocytes by calculating CL int,uptake,total (eq. 5) significantly improved the IVIVE of CL hepatic.

The loss of polarity of the isolated hepatocytes used in cell suspension or short-term cultures results in both basolateral (sinusoidal, facing the circulation) and apical (canalicular, facing the bile) efflux transporters exporting compound into the same medium compartment. The presence of sinusoidal efflux could therefore lead to overprediction of biliary CL for certain compounds because the measured CL int,efflux will be overestimated and contain both canalicular and sinusoidal efflux. As can be inferred from eq. 3, biliary efflux will be overpredicted by a factor of 2 if sinusoidal and canalicular efflux are of the same magnitude (CL int,efflux = CL int,back).

Little is known of basolateral efflux for the study compounds. Digoxin is an OST–OSTβ substrate (Seward et al., 2003), but nothing is known of its in vivo significance. Fexofenadine is a MRP3 substrate in mouse liver where sinusoidal and basolateral fexofenadine effluxes are of similar magnitude (Matsushima et al., 2008; Tian et al., 2008). Mice have been shown to express high levels of MRP3 compared with rats, where basolateral efflux thus might be less pronounced (Chu et al., 2006). Likewise, rosuvastatin has recently been shown to exhibit similar basolateral and canalicular efflux in rat SCH, after the large up-regulation of MRP3 and rMRP4 taking place in rat SCH (Pfeifer et al., 2013). The error introduced by basolateral efflux in short-term plated rat hepatocytes is thus likely to be small for these compounds.

In the liver, most sinusoidal efflux transporters show low expression compared with the canalicular ones; MRP3 is barely detectable in rat liver and short-term hepatocyte cultures whereas MRP2 shows very high expression (Rippin et al., 2001; Luttringer et al., 2002). The expression of rMRP2 in rat liver is more than twice the combined levels of rMRP3 and rMRP4 (Rippin et al., 2001; Luttringer et al., 2002; Jigorel et al., 2005). It is known that for some drug metabolites, particularly sulfate conjugates, the sinusoidal efflux may be very high, but data on parent compounds are scarce, so this area merits further study (Zamek-Gliszczynski et al., 2006). In the present study, CL bile was not overpredicted when scaling from in vitro CL int,efflux, and the rank orders for in vitro efflux and CL bile were identical, suggesting that basolateral efflux was not a major component in the efflux of the tested compounds.

Compounds with high passive permeability may also present a problem in the experimental model as this component may be difficult to determine experimentally. The biliary cleared compound set used consists of low permeable BDDCS class III compounds (Lavé et al., 1999; Benet et al., 2011). For rosuvastatin and fexofenadine, the passive uptake component has been estimated to be less than 10% of the total hepatocyte uptake and is thus unlikely to have a major impact on measurements (Menochet et al., 2012a).

In conclusion, we have developed an experimental technique based on short-term plated hepatocytes that allows the measurement of uptake, metabolism, and efflux of drug compounds. Basolateral efflux is, however, not considered and may introduce errors into the predictions. In vitro efflux measurements using this model predicted biliary clearance within or close to 2-fold of measured in vivo values for four compounds—digoxin, fexofenadine, napsagatran, and rosuvastatin—that exhibit a wide range of in vivo biliary clearances. Efflux-corrected in vitro uptake measurements were used to improve the IVIVE of hepatic CL. The short-term hepatocyte culture model described thus provides a simple way to study uptake, metabolic, and efflux clearance pathways in the liver of new chemical entities and
considerably improves the prediction of hepatic clearance, especially for compounds with a large biliary clearance component.

Acknowledgments
The authors thank Annalie Bengtsson, Jessie Dahlström, Eva Floby, and Stefan Martinsson for their great and generous help.

Authorship Contributions
Participated in research design: Lundquist, Lööf, Fagerholm, Sjögren, Briem, Johansson, Afzelius, Andersson.

Conducted experiments: Lundquist, Lööf, Sjögren, Briem, Johansson.

Contributed new reagents or analytic tools: Lundquist, Johansson, Briem, Fagerholm.

Performed data analysis: Lundquist, Lööf, Fagerholm.

Wrote or contributed to the writing of the manuscript: Lundquist, Fagerholm, Briem, Johansson, Hooogstraate, Afzelius, Andersson.

References


Address correspondence to: Tommy B. Andersson, Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. E-mail: tommy.b.andersson@astrazeneca.com